Published in Psychooncology on November 11, 2010
Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev (2011) 1.13
A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer (2011) 1.01
Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. Br J Cancer (2013) 0.90
A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. Genet Med (2015) 0.89
BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol (2015) 0.82
Adaptation to bipolar disorder and perceived risk to children: a survey of parents with bipolar disorder. BMC Psychiatry (2013) 0.82
How can psychological science inform research about genetic counseling for clinical genomic sequencing? J Genet Couns (2014) 0.81
Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet (2015) 0.77
Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study. BMC Cancer (2016) 0.75
Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires-an Italian exploratory study. J Cancer Res Clin Oncol (2015) 0.75
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol (2005) 2.33
Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol (2003) 2.33
Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum (2002) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology (2008) 1.79
Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg (2006) 1.70
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol (2003) 1.68
Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making (2004) 1.63
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
Exploring the reference point in prospect theory: gambles for length of life. Med Decis Making (2006) 1.59
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58
Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord (2006) 1.57
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet (2010) 1.54
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49
Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord (2004) 1.48
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res (2003) 1.44
PICK1 deficiency impairs secretory vesicle biogenesis and leads to growth retardation and decreased glucose tolerance. PLoS Biol (2013) 1.41
Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat (2009) 1.41
The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology (2004) 1.41
Autosomal recessive HEM/Greenberg skeletal dysplasia is caused by 3 beta-hydroxysterol delta 14-reductase deficiency due to mutations in the lamin B receptor gene. Am J Hum Genet (2003) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res (2007) 1.40
Developing a policy for paediatric biobanks: principles for good practice. Eur J Hum Genet (2012) 1.39
Genetic risk estimation by healthcare professionals. Med J Aust (2005) 1.39
Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology (2005) 1.39
[Decision-making in preoperative radiotherapy in rectal cancer: variation in provision of information]. Ned Tijdschr Geneeskd (2015) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Empirical data and moral theory. A plea for integrated empirical ethics. Med Health Care Philos (2004) 1.36
Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord (2006) 1.36
Self-reports of health-care utilization: diary or questionnaire? Int J Technol Assess Health Care (2005) 1.35
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Med Genet (2006) 1.29
Postoperative anemia after joint replacement surgery is not related to quality of life during the first two weeks postoperatively. Transfusion (2011) 1.26
Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A (2004) 1.25
How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol. Implement Sci (2010) 1.24
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 1.22
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res (2009) 1.22
Cost measurement in economic evaluations of health care: whom to ask? Med Care (2004) 1.22
Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer (2007) 1.21
Genetic testing in familial melanoma: uptake and implications. Psychooncology (2008) 1.21
Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. J Invest Dermatol (2007) 1.21
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat (2010) 1.20
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat (2006) 1.18
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat (2007) 1.16
Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol (2004) 1.16
Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol (2002) 1.15
Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol (2006) 1.15
Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health (2009) 1.15
How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf (2013) 1.14
The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology (2008) 1.12
Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J Clin Psychiatry (2008) 1.11
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol (2010) 1.11
Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet (2005) 1.10
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. Patient Educ Couns (2006) 1.10
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat (2008) 1.09
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res (2011) 1.09
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psychooncology (2007) 1.07
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer (2003) 1.07
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer (2009) 1.05
Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol (2004) 1.04
Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol (2013) 1.04
Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet (2013) 1.04
Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol (2004) 1.04
Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. BMJ (2013) 1.04
Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol (2004) 1.03
Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer (2005) 1.03
A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat (2010) 1.02
The construction of standard gamble utilities. Health Econ (2008) 1.02
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer (2009) 1.02
Theory-informed design of values clarification methods: a cognitive psychological perspective on patient health-related decision making. Soc Sci Med (2012) 1.02
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet (2013) 1.01
A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer (2011) 1.01